Advertisement
UK markets closed

  • FTSE 100

    8,213.49
    +41.34 (+0.51%)
     

  • FTSE 250

    20,164.54
    +112.21 (+0.56%)
     

  • AIM

    771.53
    +3.42 (+0.45%)
     

  • GBP/EUR

    1.1652
    -0.0031 (-0.26%)
     

  • GBP/USD

    1.2546
    +0.0013 (+0.11%)
     

  • Bitcoin GBP

    50,115.99
    +2,799.15 (+5.92%)
     

  • CMC Crypto 200

    1,365.62
    +88.64 (+6.94%)
     

  • S&P 500

    5,127.79
    +63.59 (+1.26%)
     

  • DOW

    38,675.68
    +450.02 (+1.18%)
     

  • CRUDE OIL

    77.99
    -0.96 (-1.22%)
     

  • GOLD FUTURES

    2,310.10
    +0.50 (+0.02%)
     

  • NIKKEI 225

    38,236.07
    -37.98 (-0.10%)
     

  • HANG SENG

    18,475.92
    +268.79 (+1.48%)
     

  • DAX

    18,001.60
    +105.10 (+0.59%)
     

  • CAC 40

    7,957.57
    +42.92 (+0.54%)
     
MONEY:

Best savings accounts that offer above inflation rates

Where to find a top-rated deal that works for you

New drugs help GSK offset drag of flagging Advair sales

Reuters - UK Focus

(Repeats with no change in text)

LONDON, Feb 3 (Reuters) - Growing demand for new drugs helped GlaxoSmithKline (Other OTC: GLAXF - news) beat forecasts for fourth-quarter earnings by a small margin on Wednesday, offsetting a continued slide in sales of its older Advair respiratory medicine.

Sales, in sterling terms, rose 2 percent to 6.29 billion pounds ($9.12 billion) in the three months ended Dec. 31, generating core earnings per share (EPS) down 34 percent at 18.1 pence.

Analysts on average had forecast sales of 6.25 billion pounds and core EPS, which excludes certain items, of 17.9p, according to Thomson Reuters (Dusseldorf: TOC.DU - news) . (Reporting by Ben Hirschler; Editing by Elaine Hardcastle)